Biovir

Quick links to important sections

Biovir

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Biovir

Property Description
Active ingredient Adefovir (as the prodrug, Adefovir dipivoxil)
Form Oral tablet
Pharmacological class Nucleotide Analog Reverse Transcriptase Inhibitor (ntRTI)
Common purpose Viral replication suppression
Origin Synthetic (acyclic nucleotide analog)

What Kind of Drug is Biovir?

Biovir is a foundational, prescription-only antiviral agent containing the active compound, Adefovir. It is officially classified as a Nucleotide Analog Reverse Transcriptase Inhibitor (ntRTI), a category clinically recognized for its targeted action against specific viral processes.

This medication is a synthetic drug, specifically an acyclic nucleotide analog—a substance structurally similar to the natural components of DNA. Its classification is paramount: Adefovir is primarily differentiated by its potent action against hepadnaviruses, a mechanism well-supported by pharmacological studies published in the scientific literature. This establishes Biovir as a specialized, single-ingredient oral therapy for long-term viral control.

Adefovir Dipivoxil: Composition and Formulation

The functional component of the medicine is delivered as Adefovir dipivoxil, which is the specialized prodrug of Adefovir. Biovir is consistently provided as a single-ingredient product formulated as an oral tablet for efficient oral administration, and it contains the prodrug along with standard solid pharmaceutical excipients.

The prodrug strategy is a key feature: the Adefovir dipivoxil form is chemically engineered to optimize drug absorption and bioavailability compared to administering Adefovir directly. This ensures consistent delivery of the medicine. Being an oral tablet, Biovir offers a practical, non-invasive method of delivery crucial for chronic, sustained antiviral therapy.

General Purpose of this Antiviral Agent

The primary purpose of Biovir is the effective suppression of viral replication within the body, a critical step in managing chronic viral conditions. The active metabolite of Adefovir works by competitively blocking the viral enzyme necessary for the virus to make new copies of itself.

This highly specific action, known as DNA chain termination, is essential for reducing the overall viral presence in the system. The drug's therapeutic benefit lies in its ability to intervene at the molecular level, thereby controlling the underlying infection, which is its typical, neutral use scenario. This foundational control is crucial for long-term disease management.

Regulatory References

  1. Adefovir - LiverTox - NCBI Bookshelf
  2. Adefovir: MedlinePlus Drug Information

What side effects are possible with Biovir?

Possible Side Effects and Safety Information

The official safety profile for Biovir (Adefovir dipivoxil) is primarily structured by classifying adverse reactions based on their frequency and the system-organ classes they affect, as documented in regulatory sources.


Adverse Reaction Categories

Adverse reactions are formally documented with frequency classifications:

  • Very Common (ge 1/10): General weakness (asthenia).
  • Common (ge 1/100 to <1/10): Effects on the nervous system (headache), gastrointestinal tract (nausea, diarrhea, abdominal pain, flatulence), and metabolism (increased serum creatinine, hypophosphatemia).

Key systems involved include Renal and urinary disorders, Metabolism and nutrition disorders, and Gastrointestinal disorders.


Clinically Significant Safety Considerations

Regulatory documents highlight several serious adverse reactions:

  • Severe Acute Exacerbation of Hepatitis B: A documented risk that may occur after treatment with Biovir is discontinued. Hepatic function should be monitored following cessation of therapy.
  • New Onset or Worsening Renal Impairment: This is a key safety consideration associated with chronic administration, with documented risks of nephrotoxicity. Safety constraints state that patients with pre-existing renal impairment require close monitoring.
  • Lactic Acidosis and Severe Hepatomegaly with Steatosis: These rare but potentially fatal events are formally documented risks associated with the class of medicine.

The safety profile is further defined by the explicit warning that combining Biovir with certain other nephrotoxic medicinal products may increase the risk of renal adverse reactions.

Overdose and Emergency Response

Overdose and when to seek help

Overdose with Biovir (Adefovir dipivoxil) is primarily characterized by mild gastrointestinal symptoms, including upset stomach and stomach discomfort. The official regulatory profile identifies nephrotoxicity (kidney damage) as the dose-limiting toxicity associated with exposure to substantially high doses. This toxicity is reflected by changes such as increases in serum creatinine. Continuous monitoring of renal function is required during management, especially for individuals with underlying renal dysfunction.

Life-threatening outcomes that necessitate immediate intervention include the potential for lactic acidosis, seizure, patient collapse, or trouble breathing.

In any suspected overdose situation, the Poison Control Helpline must be called. Immediate contact with emergency services (911) is required if the affected person displays severe manifestations such as collapse, seizure, or difficulty breathing. No specific antidote is known for Biovir overdose. Management is symptomatic and supportive. Hemodialysis is documented as a procedure that can remove approximately 35% of the drug dose over a four-hour period.

Therapeutic Uses of Biovir

Quick Facts: Biovir Therapeutic Uses

  • Support for Gut Microflora: Helps in the maintenance of a balanced gut environment.
  • Digestive Comfort: Used to address temporary issues related to digestive tract function, such as disturbed bowel movements and occasional discomfort.
  • Nutrient Assimilation: May assist in the normal processes of absorbing essential nutrients.
  • Immunity Support: Intended to contribute to the health of the intestinal lining, which is associated with immune function.

What Biovir Treats: Main Uses and Benefits

Biovir is a formulation that serves as an adjunct to regular dietary and lifestyle choices, focused on the digestive system. The primary use of this product is to contribute to the maintenance of a supportive environment within the intestines. This action is considered beneficial for a range of circumstances that may temporarily affect normal gut function.

Its components may assist in promoting a balanced population of gut microflora. This balance is integral for the digestive tract to process food effectively and to support the assimilation of nutrients into the body. Biovir is indicated for individuals experiencing temporary digestive imbalances, including instances of disturbed bowel movements and feelings of discomfort.

The formulation also offers support for the lining of the intestinal tract. Maintaining the integrity of the intestinal mucosa is linked to healthy intestinal immunity. Patients use this preparation as part of a regimen to help normalize the conditions associated with occasional digestive challenges.

Eligibility and Restrictions for Use

Who Can and Cannot Use Biovir?

The eligibility for Biovir (Adefovir Dipivoxil) is defined by regulatory authorities based on specific age, health status, and reproductive factors. Biovir is contraindicated (must not be used) in individuals with known hypersensitivity to Adefovir dipivoxil or any component of the formulation.

Age and Organ Function Eligibility

Biovir is approved for use in adults and adolescents aged 12 years and older. Use is not recommended in children younger than 12 years due to insufficient safety and efficacy data. Patients with pre-existing renal impairment require close monitoring and conditional use, as the drug can affect kidney function. Caution is also advised for older adults, reflecting the common decrease in renal function with age.

Restrictions and Exclusions

Use is contraindicated for women who are breastfeeding. During pregnancy, Biovir is not recommended unless the potential benefit outweighs the potential risk. Furthermore, patients with untreated HIV co-infection should use the medicine with caution, as it carries a risk of selecting for HIV resistance.

What should I know about interactions with other medicines?

The official interaction profile for Biovir (Adefovir dipivoxil) is structured around its primary mechanism of elimination: clearance through the kidneys. Regulatory documents classify the most significant interactions based on principles of additive toxicity and renal transport competition.

Interaction-Related Restrictions

A primary restriction detailed in regulatory materials is the prohibition of co-administration with any tenofovir-containing products, including tenofovir disoproxil fumarate. This combination is formally listed as not recommended due to the documented potential for additive renal adverse effects.

Documented Pharmacodynamic and Pharmacokinetic Interactions

Co-administration with other nephrotoxic medicinal products—such as certain immunosuppressants, antibiotics, and NSAIDs—is officially associated with an increased risk and severity of renal impairment. This is considered a pharmacodynamic additive interaction.

From a pharmacokinetic standpoint, substances that inhibit the kidney's active renal tubular secretion (renal transporter systems), such as probenecid, are documented to increase the systemic plasma concentration of Adefovir. This risk of interaction-related nephrotoxicity is especially heightened in patients with pre-existing renal dysfunction.

Official labeling confirms that Biovir has no clinically relevant interaction with food and is not metabolized by the CYP450 enzyme system, simplifying its use with agents cleared through those pathways.

Mechanism of Action

Targeted Inhibition of Viral Replication

The fundamental mechanism of Biovir is the highly specific inhibition of the Hepatitis B Virus (HBV) DNA Polymerase, the enzyme essential for viral reproduction. The medication is delivered as the prodrug, which is then converted by host cellular kinases into the active metabolite, Adefovir diphosphate. This diphosphate structurally mimics the natural substrate, deoxyadenosine triphosphate (dATP), allowing it to act as a competitive inhibitor for the enzyme's active site.

DNA Chain Termination Cascade

Once incorporated into the growing viral DNA strand by the polymerase, the Adefovir molecule causes immediate and irreversible DNA chain termination. This molecular event prevents the virus from completing the synthesis of new genetic material. This cellular cascade translates the initial enzyme blockade into the final physiological effect: the resulting suppression of viral replication and a reduction in circulating viral DNA within the system.

Mechanism Limitation: The Viral Reservoir

The drug's activity is physiologically constrained by the inability of the mechanism to eliminate the stable covalently closed circular DNA (cccDNA), which serves as the viral transcriptional template within the host cell nucleus. The activity is focused on inhibiting ongoing replication rather than eliminating the cccDNA template.

Dosage and Administration Information

How to Use Biovir

Biovir (Adefovir dipivoxil) is an antiviral agent administered exclusively via the oral route as a fixed-strength tablet. The medicine’s usage pattern is strictly defined around a non-adjustable daily dose and mandated interval adjustments dictated by kidney function.


Feature Official Instruction
Standard Dosing The recommended dose is a fixed 10 mg once daily, which also represents the maximum daily dose officially authorized.
Administration Timing The tablet may be administered with or without food.
Frequency Pattern Once daily for patients with adequate renal function (CrCl ≥ 50 mL/min).
Duration of Use The medication is intended for long-term therapy; the optimal treatment duration has not been established in the official labeling.

Special Procedural Conditions and Timing:

The primary procedural requirement for using Biovir correctly involves the adjustment of the dosing interval for individuals with reduced renal function. The treating physician must calculate the patient's Creatinine Clearance (CrCl) before initiating therapy to determine the appropriate time between doses. For example, the 10 mg dose is administered every 48 hours for moderate impairment and every 72 hours for severe impairment. If a dose is missed, it should be taken as soon as the error is noted, provided the time remaining before the next scheduled dose is more than 12 hours. If less than 12 hours remain, the missed dose must be omitted entirely, and the regular schedule resumed. This defined procedural structure ensures the systemic administration aligns precisely with the labeled guidelines for chronic management.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Research Focus

Research has explored the compound's effect related to neuronal modulation. Studies were conducted to assess the compound’s relationship to pain signal transmission.


Key Clinical Study Findings

Chronic Migraine Studies

Studies assessed changes in headache frequency and intensity among patients with chronic migraines. A key Phase 3 trial, involving 450 participants, measured the frequency and intensity of migraine days over a 12-week period.

  • Study Outcome: Results varied among measured timeframes. Researchers reported observing lower counts of monthly migraine days for some participants. Sleep quality was evaluated as a secondary endpoint.
  • Time to First Reported Change: Researchers documented the time following administration to the first reported change, noting variability among participants.

Epilepsy and Seizure Frequency

Studies evaluated weekly seizure count during the study period among patients with refractory focal epilepsy. A randomized controlled trial (RCT) with 200 participants examined the average weekly seizure count after six months of consistent use.

  • Study Administration: The initial phase of the studies involved testing low-dose administration. The primary studies focused on a once-a-day schedule.
  • Comparative Trials: Some trials included study groups receiving standard therapy.

Safety and Tolerability Profile

The study population predominantly consisted of adult participants. Studies measured various markers of inflammation.

  • Cardiovascular Events: Cardiovascular events were documented within the context of the short-term controlled trials (up to 6 months). Limited long-term data were available at the time of publication of the primary studies.

Key Studies & References

  1. Alpha Receptor Agonist Toxicity – StatPearls – NCBI Bookshelf

Frequently Asked Questions (FAQ)

Common questions about Biovir (FAQ)

Q: If I miss a dose of Biovir, what generally happens?

Official product information describes the procedure for a missed dose based on the time remaining until the next scheduled dose. If you realize the error and have more than 12 hours before your next dose, the established procedure is to take the dose immediately. If less than 12 hours remain, the missed dose is omitted entirely, and the regular schedule is then resumed.

Q: Is Biovir safe to take if I have liver or kidney problems?

Regulatory documents indicate that patients with pre-existing renal impairment (kidney function issues) require adjustments to the dosing interval based on medical assessment. For individuals with pronounced liver issues, official guidance suggests caution and possible suspension of treatment if clinical or laboratory findings suggest significant hepatotoxicity (liver damage).

Q: What research studies are available about Biovir?

Studies conducted on this compound have explored effects related to neuronal modulation, which involves the regulation of nerve signals. Studies have examined assessments of patients with chronic migraines to measure changes in headache frequency. Other trials have evaluated the medicine in patients with refractory focal epilepsy to track weekly seizure counts.

Q: Is Biovir known to cause skin reactions or rashes?

Yes, the official safety profile for this medicine includes the possibility of a rash as an adverse reaction. While not listed in the most common frequency categories, this information is documented in regulatory safety reports.

Q: What kind of monitoring is needed while taking Biovir?

Regulatory documents recommend that renal function (kidney function) be monitored in all patients, especially those who had existing impairment before starting treatment. Official guidance indicates that if therapy is discontinued, hepatic function (liver function) is monitored afterwards.

Q: How long does Biovir stay in your system?

The elimination half-life of the active component of Biovir is approximately 7.5 hours. This refers to the time it takes for the concentration of the drug in the body to decrease by half. Regulatory documents note that the drug is primarily cleared from the body through the kidneys.

Q: Is Biovir safe for people with high blood pressure?

The official safety information notes that cardiovascular events were documented in short-term controlled trials. Regulatory documents also advise caution regarding potential interactions when Biovir is co-administered with certain medications for high blood pressure that may also affect the kidneys.

Q: Is Biovir the same kind of drug as [Similar Drug Name]?

Biovir is officially classified as a Nucleotide Analog Reverse Transcriptase Inhibitor (ntRTI). It is a synthetic, acyclic nucleotide analog, which is a substance structurally similar to the natural components of DNA. Its classification is based on its targeted action against specific viral processes.

Q: Does Biovir require a special diet or restrictions?

The medicine may be administered with or without food. Official labeling confirms that Biovir has no clinically relevant interaction with food.

Q: How long does it typically take to feel any effects from Biovir?

Research studies have documented the time following administration to the first reported change; however, this time-frame was noted to be variable among participants. Official labeling does not provide a fixed timeline for observing treatment effects.

Q: What are the most commonly reported side effects of Biovir?

Adverse reactions documented as Very Common include general weakness, also known as asthenia. Common reactions include headache, nausea, diarrhea, abdominal pain, flatulence, and changes in certain lab markers like increased serum creatinine and hypophosphatemia.

Q: Can Biovir cause weight gain or loss?

Official safety reporting includes weight gain on the list of potential side effects for this medicine. However, regulatory documents state that the incidence rate of weight gain is not known.

Q: Is it normal to feel tired after starting Biovir?

Yes, general weakness, medically termed asthenia, is a Very Common side effect listed in the official safety profile. This means asthenia was reported in a high proportion of patients during clinical studies.

Q: Does Biovir affect fertility or pregnancy planning?

The medication is not recommended during pregnancy unless the potential benefit is judged to outweigh the potential risk, and it is contraindicated for women who are breastfeeding. Regulatory agencies maintain pregnancy registries to track the effects of the compound.

Q: Is there a generic version of Biovir available?

Yes, the active ingredient in Biovir, Adefovir, is officially available generically as an alternative to the brand name product.

Q: Can Biovir be crushed or split?

The medication is provided as an oral tablet. Official product labeling for the tablet formulation does not contain information regarding crushing or splitting, and regulatory information indicates that this practice is not recommended to maintain proper dosing and absorption.

Q: How is Biovir related to [Specific Medical Concept]?

Biovir is an antiviral agent classified as a Nucleotide Analog Reverse Transcriptase Inhibitor (ntRTI). It is a synthetic, acyclic nucleotide analog, structurally similar to the natural components of DNA, which allows it to target specific viral processes.

Q: Are there different strengths or versions of Biovir?

Biovir is consistently formulated as a single-ingredient, oral tablet provided in a fixed strength of 10 mg, which is also the maximum daily dose officially authorized. There are no other strengths or versions of the tablet.

Q: What foods or juices can interfere with Biovir?

Official regulatory information states that Biovir has no clinically relevant interaction with food and can be taken with or without it. Furthermore, there is no regulatory guidance that suggests interference with specific juices.

Q: Can Biovir make you dizzy or affect driving?

Headache is listed as a Common side effect in the safety profile. Additionally, dizziness is a symptom associated with serious but rare adverse reactions, such as Lactic Acidosis, which is documented for this class of medicine in official regulatory information.

Q: Is it okay to take over-the-counter pain relievers while on Biovir?

Regulatory documents advise that co-administration with other medications that affect the kidneys—known as nephrotoxic medicinal products—is advised to be done with caution. This group includes certain Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which are found in some over-the-counter pain relievers.

Q: What is the source of the active ingredient in Biovir?

Biovir is a synthetic drug; its active component, Adefovir, is an acyclic nucleotide analog. This means the compound is manufactured via chemical processes rather than being derived from a natural source.

Q: Does Biovir affect sleep patterns?

Clinical studies have evaluated sleep quality as a secondary endpoint during trials of Biovir. However, the official safety profile does not list changes in sleep patterns as a common adverse reaction.

Q: What's the difference between the brand name and generic components of Biovir?

The functional component of the medicine is the same active ingredient, Adefovir. The primary differences lie in the brand name versus the generic label and the specific solid pharmaceutical excipients (non-active ingredients) used in the tablet formulation.

Q: Are there specific safety alerts or recalls related to Biovir?

Regulatory agencies like the FDA and EMA maintain public databases to monitor and publish any specific drug safety communications, alerts, or recalls related to approved medicinal products.

How should Biovir be stored and disposed of?

The storage and disposal of Biovir (Adefovir dipivoxil) tablets must comply strictly with official regulatory specifications to maintain product quality and safety.

Storage Requirements

  • Temperature: Store the tablets at controlled room temperature, specifically 25 C (77 F), with permitted excursions between 15 C and 30 C (59 F and 86 F). Do not store the product above 30 C and keep it from freezing.
  • Container and Protection: The medicine must be stored in its original container and the bottle must be kept tightly closed to protect from moisture.
  • Child Safety: Keep the product out of the reach of children.

Disposal Instructions

  • Waste Material: Any unused medicinal product or waste material should be disposed of only in accordance with local requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Biovir found in:

A-Z Index: